Aptalis Pharma knows its ABCs when it comes to treating CF and GI ailments. The company develops and sells drugs mainly to treat cystic fibrosis (CF) and gastrointestinal (GI) conditions. Its Urso line treats liver disease; Carafate and Sulcrate treat ulcers; and Canasa and Salofalk offer relief for inflammatory bowel diseases. In addition, Aptalis Pharma markets Zenpep and other digestive drugs for patients with exocrine pancreatic insufficiency, a condition associated with CF. The firm's products are primarily sold in North America and the European Union. Aptalis Pharma was a subsidiary of Axcan Holdings, which is controlled by TPG Capital, but it was acquired by Forest Labs in 2014.